A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading ->
Much more global attention needs to be paid to developing early therapeutics to protect patients with COVID-19 from “hospitalisation, intensive care, or worse”, according to a report from Drugs for Neglected Diseases initiative (DNDi) released on Thursday. In addition, the few innovative treatments that exist are mostly available in high-income countries, and DNDi warns that […] Continue reading ->
In the midst of the COVID-19 pandemic, a “silent pandemic” of drug resistance to mutated bacteria, viruses and parasites is gaining ground and requires major government investments in antibiotic research and development (R&D), a group of experts has warned. “People are dying across the world from drug-resistant infections. This is a problem of today, and […] Continue reading ->
Global health experts expressed their frustration with the lack of research and attention towards neglected tropical diseases (NTDs) and vulnerable populations, calling for health systems to address NTDs in a more sustainable and holistic way. Speaking at the launch of a new strategic plan for the Geneva-based Drugs for Neglected Diseases initiative (DNDi) on Tuesday, […] Continue reading ->
Thirteen African countries and an international network of research institutions have joined forces to launch a multi-country clinical trial of COVID-19 drug treatments in Africa for people who are mild to moderately ill. The new ANTICOV trial, led by the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) aims to respond to the urgent need to […] Continue reading ->
As the 73rd World Health Assembly approaches, the European Union-sponsored draft resolution on the COVID-19 response is gathering steam and storm as it rolls closer to the planned opening of the Assembly on 18 May – with far less clarity about how it might actually hit the shores of the public debate.  The resolution aims […] Continue reading ->
Funding to develop new drugs for some of the world’s leading infectious disease killers, such as HIV/AIDS, TB and malaria, reached a record high of US $4 billion in 2018, with private sector investment driving much of the increase, according to the 2019 G-FINDER Report, which tracks such investments globally. However, investments in neglected tropical […] Continue reading ->
Neglected tropical diseases (NTDs) can lead to physical disfiguration, stress and stigmatization, which leave lifelong impacts on the mental health of many of those infected, even after the disease itself is cured.  As the health community prepares to mark the first-ever World NTD Day on 30 January, Nathalie Strub-Wourgaft, director of Neglected Tropical Diseases at […] Continue reading ->
The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading ->